We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $767M
1-Year Est. Return 119.71%
This Fund
S&P 500
This Quarter Est. Return
+8.44%
1 Year Est. Return
+119.71%
3 Year Est. Return
+244.81%
5 Year Est. Return
+382.5%
10 Year Est. Return
+2,655.81%
AUM
$1.48B
AUM Growth
+$175M
Cap. Flow
-$85.7M
Cap. Flow %
-5.8%
Top 10 Hldgs %
38.11%
Holding
211
New
41
Increased
36
Reduced
32
Closed
77

Top Buys

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$10.3M
2
IOVA icon
Iovance Biotherapeutics
IOVA
+$9.84M
3
HOWL icon
Werewolf Therapeutics
HOWL
+$9.68M
4
ALT icon
Altimmune
ALT
+$9.34M
5
TWLO icon
Twilio
TWLO
+$9.2M

Top Sells

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$49.7M
2
ABBV icon
AbbVie
ABBV
+$26.3M
3
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$12.9M
4
BMY icon
Bristol-Myers Squibb
BMY
+$12.6M
5
PANW icon
Palo Alto Networks
PANW
+$10.4M

Sector Composition

Rank Sector Weight
1 Healthcare 55.27%
2 Miscellaneous 26%
3 Technology 8.46%
4 Industrials 5.02%
5 Financials 2.2%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INBX
76
DELISTED
Inhibrx, Inc. Common Stock
INBX
$5.2M 0.35%
189,083
+74,440
+65% +$1.55M
ATER icon
77
CALL
Aterian
ATER
$12.4M
$5.2M 0.35%
29,633
– –
CRIS icon
78
Curis
CRIS
$2.64M
$4.75M 0.32%
1,471
-744
-34% -$3.36M
CVRX icon
79
CVRx
CVRX
$79.9M
$4.2M 0.28%
+150,000
New +$4.2M
RUN icon
80
Sunrun
RUN
$2.1B
$4.02M 0.27%
+72,000
New +$3.48M
NBP
81
NovaBridge Biosciences American Depositary Shares
NBP
$189M
$3.89M 0.26%
46,350
-8,612
-16% -$568K
SGTX
82
DELISTED
Sigilon Therapeutics, Inc. Common Stock
SGTX
$3.87M 0.26%
27,711
-154
-0.6% -$27.1K
BEAM icon
83
Beam Therapeutics
BEAM
$2.55B
$3.66M 0.25%
+28,425
New +$2.26M
PLTK icon
84
Playtika
PLTK
$881M
$3.58M 0.24%
+150,000
New +$3.92M
ARKO icon
85
ARKO Corp
ARKO
$487M
$3.4M 0.23%
369,875
-38,125
-9% -$388K
ANNX icon
86
Annexon
ANNX
$791M
$3.34M 0.23%
+148,318
New +$3.29M
EUCR
87
DELISTED
Eucrates Biomedical Acquisition Corp. Ordinary Shares
EUCR
$3.24M 0.22%
329,025
+25,000
+8% +$246K
ISEE
88
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$3.15M 0.21%
+500,000
New +$3.23M
RPTX
89
DELISTED
Repare Therapeutics
RPTX
$3.13M 0.21%
100,391
-147,709
-60% -$4.84M
GRCL
90
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
$3.04M 0.21%
233,850
+21,250
+10% +$285K
BGMS
91
Bio Green Med Solution Inc
BGMS
$5.82M
$3.01M 0.2%
141
– –
NEXN
92
Nexxen International
NEXN
$511M
$2.98M 0.2%
+150,000
New +$2.81M
VINC
93
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
$2.96M 0.2%
11,373
+6,688
+143% +$2.04M
S icon
94
SentinelOne
S
$8.07B
$2.91M 0.2%
+68,400
New +$2.91M
PMVP icon
95
PMV Pharmaceuticals
PMVP
$78M
$2.87M 0.19%
84,074
+40,718
+94% +$1.36M
ACHL
96
DELISTED
Achilles Therapeutics
ACHL
$2.86M 0.19%
292,194
-7,806
-3% -$106K
ARGX icon
97
argenx
ARGX
$62.3B
$2.79M 0.19%
9,249
– –
KRRO icon
98
Korro Bio
KRRO
$174M
$2.74M 0.19%
+5,503
New +$2.69M
CYT
99
DELISTED
Cyteir Therapeutics, Inc. Common Stock
CYT
$2.67M 0.18%
+125,000
New +$2.34M
PRGO icon
100
Perrigo
PRGO
$1.87B
$2.41M 0.16%
+52,500
New +$2.33M
2 3
4
5 6

Similar funds

ISWM
Independent Solutions Wealth Management Williamsville, New York $766M AUM 31.53% 1-Year Est. Return
ACP
Albar Capital Partners London, United Kingdom $767M AUM 61.96% 1-Year Est. Return
NIM
Nexus Investment Management Toronto, Ontario, Canada $767M AUM 30.97% 1-Year Est. Return
ACM
Arvin Capital Management Austin, Texas $766M AUM 36.51% 1-Year Est. Return
CBT
Crews Bank & Trust Wauchula, Florida $766M AUM 19.5% 1-Year Est. Return
SPIA
Strategic Point Investment Advisors Providence, Rhode Island $767M AUM 17.58% 1-Year Est. Return
CNB
Camden National Bank Camden, Maine $767M AUM 14.32% 1-Year Est. Return
HI
Hendershot Investments Centreville, Virginia $766M AUM 10.81% 1-Year Est. Return

Sphera Funds Management's Q2 2021 Portfolio in Review

As of Q2 2021, Sphera Funds Management held 211 positions worth $1.48B, up 13% from $1.3B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Sphera Funds Management withdrew a net $85.7M in Q2 2021, closing 77 positions and reducing 32 holdings. Its most notable exit was Bristol-Myers Squibb, an estimated $12.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 55% of assets, down from 63% a quarter earlier, followed by Miscellaneous and Technology.

Against the trend, Sphera Funds Management opened a new position in Iovance Biotherapeutics worth $9.85M.

  • Sphera Funds Management's largest Q2 2021 buy was Iovance Biotherapeutics: 378,642 shares worth $9.85M.
  • Sphera Funds Management added most to AstraZeneca in Q2 2021, an estimated $10.3M increase.
  • Sphera Funds Management's biggest Q2 2021 reduction was Eli Lilly, cutting an estimated $49.7M.
  • Sphera Funds Management fully exited Bristol-Myers Squibb in Q2 2021, selling an estimated $12.6M.
  • Sphera Funds Management's ten largest holdings make up 38% of its $1.48B portfolio in Q2 2021.
  • Sphera Funds Management opened 41 new positions and closed 77 in Q2 2021.
  • Sphera Funds Management's portfolio value rose 13% quarter-over-quarter to $1.48B.

Based on Sphera Funds Management's 13F filing for Q2 2021, filed 17 Aug 2021.